Table 4 Normalized expressions (2^(−Avg.(Delta(Ct)) of hsa-miR-181a-5p and RNU6–2 in Group 1 (CML patients responsive to imatinib therapy), and Control Group (blood donors) calculated by Gene Globe Data Analysis Centre (QIAGEN)
|  | Average Ct | Average Delta(Ct) (Ct(miROI) - Average Ct(normalisation factor)) | 2^(−Average (Delta(Ct)) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mature ID | Control Group | Standard Deviation | Group 1 | Standard Deviation | Control Group | Standard Deviation | Group 1 | Standard Deviation | Control Group | Group 1 |
hsa-miR-181a-5p | 24.99 | 0.804605 | 25.86 | 0.764923 | 5.146885 | 0.734814 | 6.241981 | 0.588011 | 0.028225 | 0.013212 |
RNU6–2 | 20.06 | 0.828910 | 20.90 | 0.754208 | 0.212599 | 0.610294 | 1.281648 | 0.640244 | 0.862981 | 0.411325 |